通过彻底改变巨细胞介导癌症免疫疗法,利用先天免疫系统
Gayatri Reghu1, Praveen Kumar Vemula, Sarita Ganapathy Bhat
1Department of Biotechnology, Cochin University of Science and Technology, Kochi 682 022, India.
Journal of biosciences
|June 12, 2024
概括
向巨细胞为固体瘤提供了一个有希望的免疫疗法策略,克服瘤微环境带来的挑战. 本综述探讨了多功能的巨细胞向方法,以提高癌症治疗疗效.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症治疗 癌症治疗
背景情况:
- 免疫疗法为传统癌症治疗提供了一个更安全的替代方案.
- 固体瘤由于其抑制性微环境和抗原异质性而存在挑战.
- 巨细胞是瘤微环境中的关键免疫细胞,使它们成为可行的治疗点.
研究的目的:
- 审查用于癌症免疫治疗的多功能巨细胞向策略.
- 讨论在固体瘤中操纵巨细胞的临床前和临床方法.
- 突出巨细胞在推进癌症治疗中的潜力.
主要方法:
- 对基于巨细胞的癌症免疫疗法现有文献的审查.
- 分析包括直接杀死,重编程和招募瘤相关巨细胞的抑制策略.
- 探索新型仿真抗原受体 (CAR) 巨细胞和基因工程巨细胞.
主要成果:
- 目前存在各种临床前和临床策略,用于向固体瘤中的巨细胞.
- 方法包括直接消除与瘤相关的巨细胞,再极化和招募封锁.
- 新型工程巨细胞 (例如,CAR巨细胞) 显示出增强抗瘤活性的潜力.
结论:
- 向巨细胞是癌症免疫治疗中的一个多功能和适应性的策略.
- 了解和利用巨细胞功能可以释放它们对抗癌症的全部治疗潜力.
- 宏细胞为中心的方法为克服当前固体瘤免疫疗法的局限性提供了一个有希望的途径.
相关概念视频
Tumor Immunotherapy
514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
Cell-mediated Immune Responses
68.1K
Overview
68.1K
Immune Surveillance by NK Cells and Phagocytes
1.4K
Immune surveillance is an integral part of the innate immune system, involving the continuous monitoring of peripheral tissues to detect and respond to pathogens, infected cells, or cancerous cells. This surveillance is conducted primarily by natural killer (NK) cells and phagocytes, which employ distinct but complementary mechanisms to identify and eliminate threats.
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
1.4K
Cancer Vaccines
354
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
354
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Cytotoxic T Cells-mediated Immune Response
891
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
891


